In vivo selection of human embryonic stem cell-derived cells expressing methotrexate-resistant dihydrofolate reductase

Human embryonic stem cells (hESCs) provide a novel source of hematopoietic and other cell populations suitable for gene therapy applications. Preclinical studies to evaluate engraftment of hESC-derived hematopoietic cells transplanted into immunodeficient mice demonstrate only limited repopulation....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gene therapy 2010-02, Vol.17 (2), p.238-249
Hauptverfasser:	Gori, J L, Tian, X, Swanson, D, Gunther, R, Shultz, L D, McIvor, R S, Kaufman, D S
Format:	Artikel
Sprache:	eng
Schlagworte:	Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Animals Applied cell therapy and gene therapy Biological and medical sciences Biomedical and Life Sciences Biomedicine Biotechnology Bone Marrow Bone marrow transplantation CD34 antigen CD45 antigen Cell Biology Cell Differentiation Cell Line Chemotherapy Diabetes mellitus Dihydrofolate reductase Drug Resistance Embryo cells Embryonic stem cells Embryonic Stem Cells - metabolism Embryos Endothelial cells Fundamental and applied biological sciences. Psychology Gene Expression Gene Therapy Genetic aspects Genetic Therapy - methods Graft Survival Health aspects Health. Pharmaceutical industry Human Genetics Humans Immunodeficiency Industrial applications and implications. Economical aspects Interleukin 2 receptors Medical sciences Methotrexate Methotrexate - pharmacology Mice Mice, Inbred NOD Mice, SCID Nanotechnology original-article Peripheral blood Physiological aspects Pluripotency Rodents Stem cell transplantation Stem Cell Transplantation - methods Stem cells Teratoma - genetics Tetrahydrofolate Dehydrogenase - genetics Tetrahydrofolate Dehydrogenase - metabolism Transfusions. Complications. Transfusion reactions. Cell and gene therapy Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!